Raymond James Financial Reiterates Outperform Rating for Dianthus Therapeutics (NASDAQ:DNTH)

by · The Markets Daily

Raymond James Financial reiterated their outperform rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a report released on Tuesday morning,Benzinga reports. They currently have a $63.00 price objective on the stock, up from their prior price objective of $56.00.

Several other analysts have also recently issued reports on DNTH. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday. Robert W. Baird increased their price target on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an “outperform” rating in a research report on Tuesday. William Blair initiated coverage on shares of Dianthus Therapeutics in a report on Wednesday, July 2nd. They issued an “outperform” rating on the stock. Guggenheim raised their target price on shares of Dianthus Therapeutics from $92.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wedbush raised their target price on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the company an “outperform” rating in a report on Thursday, August 21st. Eight investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $60.67.

View Our Latest Research Report on Dianthus Therapeutics

Dianthus Therapeutics Trading Down 0.1%

Shares of NASDAQ DNTH opened at $37.86 on Tuesday. The company has a 50 day simple moving average of $22.65 and a two-hundred day simple moving average of $20.43. Dianthus Therapeutics has a 12 month low of $13.36 and a 12 month high of $38.59. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -11.65 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.87 million. Analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current year.

Insider Buying and Selling

In related news, CFO Ryan Savitz sold 20,000 shares of Dianthus Therapeutics stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 8.15% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors have recently modified their holdings of DNTH. Price T Rowe Associates Inc. MD raised its position in shares of Dianthus Therapeutics by 21.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,468 shares of the company’s stock valued at $207,000 after acquiring an additional 1,647 shares in the last quarter. Northern Trust Corp grew its stake in shares of Dianthus Therapeutics by 21.2% in the fourth quarter. Northern Trust Corp now owns 245,523 shares of the company’s stock worth $5,352,000 after purchasing an additional 42,923 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at $59,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Dianthus Therapeutics by 9.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 54,766 shares of the company’s stock valued at $1,194,000 after buying an additional 4,518 shares during the period. Finally, Deutsche Bank AG lifted its holdings in shares of Dianthus Therapeutics by 55.9% during the fourth quarter. Deutsche Bank AG now owns 20,011 shares of the company’s stock valued at $436,000 after purchasing an additional 7,179 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

(Get Free Report)

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

See Also